Clinical trial
Bevacizumab and Irinotecan to Treat Brain Tumors
NCT00393094 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00393094 |
|---|---|
| Title | Bevacizumab and Irinotecan to Treat Brain Tumors |
| Official title | A Phase II Trial of Bevacizumab and Irinotecan for Patients With Recurrent High-Grade Gliomas Immediately Following Tumor Progression After Treatment w/Bevacizumab Alone: A Companion Trial to NCI Study 06-C-0064 (NCT00271609)(Bevacizumab Alone for Recurrent Gliomas) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | High-Grade Gliomas |
| Intervention type | Biological, Drug |
| Interventions | Bevacizumab, Irinotecan hydrochloride |
| Enrollment | 31 |
| Start date | Sep 1, 2006 |
| Primary completion | Jan 1, 2010 |
| Completion | Mar 1, 2010 |
| First posted | Oct 26, 2006 |
| Last update posted | Jul 13, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: